These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29164839)

  • 1. Residual renal and cardiovascular disease risk in conventionally-treated patients with type 2 diabetes: the potential of non-traditional biomarkers.
    Zitouni K; Steyn M; Earle KA
    Minerva Med; 2018 Apr; 109(2):103-115. PubMed ID: 29164839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus.
    McKenna K; Thompson C
    Scott Med J; 1997 Aug; 42(4):99-104. PubMed ID: 9507584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical trial of the month. The STENO-2 study: a plea for global and intensive management of the type 2 diabetic patient].
    Scheen AJ; Estrella F
    Rev Med Liege; 2003 Feb; 58(2):109-11. PubMed ID: 12693313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
    Parving HH; Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S
    Ugeskr Laeger; 2001 Oct; 163(40):5514-9. PubMed ID: 11601117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin resistance as a predictor of cardiovascular morbidity and end-stage renal disease.
    Fragoso A; Mendes F; Silva AP; Neves PL
    J Diabetes Complications; 2015; 29(8):1098-104. PubMed ID: 26066409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial dysfunction and its role in diabetic vascular disease.
    Hartge MM; Kintscher U; Unger T
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):551-60, viii-ix. PubMed ID: 16959585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular disease in diabetes mellitus type 2: a potential role for novel cardiovascular risk factors.
    Hayden JM; Reaven PD
    Curr Opin Lipidol; 2000 Oct; 11(5):519-28. PubMed ID: 11048895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection.
    Brown WV
    Am J Cardiol; 2008 Dec; 102(12A):10L-13L. PubMed ID: 19084084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetic nephropathy: can renoprotection be extrapolated to cardiovascular protection?
    Opie LH; Parving HH
    Circulation; 2002 Aug; 106(6):643-5. PubMed ID: 12163420
    [No Abstract]   [Full Text] [Related]  

  • 10. Metabolic syndrome and microangiopathy.
    Szalat A; Raz I
    Isr Med Assoc J; 2006 Jun; 8(6):424-5. PubMed ID: 16833174
    [No Abstract]   [Full Text] [Related]  

  • 11. Type 2 diabetes mellitus: prevention of macrovascular complications.
    Meeuwisse-Pasterkamp SH; van der Klauw MM; Wolffenbuttel BH
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):323-41. PubMed ID: 18327994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs: potential mediators and biomarkers of diabetic complications.
    Kato M; Castro NE; Natarajan R
    Free Radic Biol Med; 2013 Sep; 64():85-94. PubMed ID: 23770198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comprehensive Cardiovascular-Renal-Metabolic Risk Reduction Approach to Patients with Type 2 Diabetes Mellitus.
    Pagidipati NJ; Deedwania P
    Am J Med; 2021 Sep; 134(9):1076-1084. PubMed ID: 34029524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
    Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
    Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelial dysfunction and hypertension in diabetes mellitus.
    Dandona P; Chaudhuri A; Aljada A
    Med Clin North Am; 2004 Jul; 88(4):911-31, x-xi. PubMed ID: 15308385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of metformin on late diabetic complications and cardiovascular events in obese patients with type 2 diabetes].
    Christiansen AL; Madsbad S
    Ugeskr Laeger; 2002 Apr; 164(15):2022-4. PubMed ID: 11984999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing Cardiovascular Risk and Testing in Type 2 Diabetes.
    Saeed A; Ballantyne CM
    Curr Cardiol Rep; 2017 Mar; 19(3):19. PubMed ID: 28220465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant macro and microvascular complications in diabetic nephropathy.
    Alwakeel JS; Al-Suwaida A; Isnani AC; Al-Harbi A; Alam A
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):402-9. PubMed ID: 19414942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.